MA27085A1 - Formulations comprenant une cephalosporine et leur utilisation dans le traitement d'infections bacteriennes chez les chats et les chiens - Google Patents

Formulations comprenant une cephalosporine et leur utilisation dans le traitement d'infections bacteriennes chez les chats et les chiens

Info

Publication number
MA27085A1
MA27085A1 MA27689A MA27689A MA27085A1 MA 27085 A1 MA27085 A1 MA 27085A1 MA 27689 A MA27689 A MA 27689A MA 27689 A MA27689 A MA 27689A MA 27085 A1 MA27085 A1 MA 27085A1
Authority
MA
Morocco
Prior art keywords
cephalosporin
cats
dogs
treatment
formulations
Prior art date
Application number
MA27689A
Other languages
English (en)
French (fr)
Inventor
Roger Nelson Kimball
Evgenyi Yur Evich Shalaev
Brian Scott Bronk
Renuka Devi Reddy
Simon Edward Blanchflower
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27085A1 publication Critical patent/MA27085A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA27689A 2001-11-30 2004-05-20 Formulations comprenant une cephalosporine et leur utilisation dans le traitement d'infections bacteriennes chez les chats et les chiens MA27085A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33853601P 2001-11-30 2001-11-30
US39893202P 2002-07-26 2002-07-26

Publications (1)

Publication Number Publication Date
MA27085A1 true MA27085A1 (fr) 2004-12-20

Family

ID=26991236

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27689A MA27085A1 (fr) 2001-11-30 2004-05-20 Formulations comprenant une cephalosporine et leur utilisation dans le traitement d'infections bacteriennes chez les chats et les chiens

Country Status (27)

Country Link
US (1) US7378408B2 (enExample)
EP (1) EP1448234B1 (enExample)
JP (1) JP4689959B2 (enExample)
KR (1) KR100621291B1 (enExample)
CN (1) CN100502873C (enExample)
AR (1) AR037595A1 (enExample)
AT (1) ATE406916T1 (enExample)
AU (1) AU2002348986B2 (enExample)
BR (1) BRPI0214583B1 (enExample)
CA (1) CA2468708C (enExample)
CY (1) CY1108437T1 (enExample)
DE (1) DE60228749D1 (enExample)
DK (1) DK1448234T3 (enExample)
EA (1) EA008503B1 (enExample)
ES (1) ES2307800T3 (enExample)
HR (1) HRP20040487A2 (enExample)
IL (2) IL161851A0 (enExample)
IS (1) IS7214A (enExample)
MA (1) MA27085A1 (enExample)
MX (1) MXPA04003724A (enExample)
NO (1) NO334818B1 (enExample)
NZ (1) NZ532208A (enExample)
PL (1) PL212683B1 (enExample)
PT (1) PT1448234E (enExample)
TN (1) TNSN04097A1 (enExample)
TW (1) TWI248363B (enExample)
WO (1) WO2003045435A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021725A1 (it) 2002-08-01 2002-10-31 Zambon Spa Composizioni farmaceutiche ad attivita' antibiotica.
MXPA06012215A (es) * 2004-04-22 2007-04-19 Pfizer Prod Inc Metodo de estabilizacion de la sal sodica cefovecina desordenada.
EP1656930A1 (en) * 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
MX2007007235A (es) * 2004-12-17 2007-10-19 Venus Remedies Ltd Combinacion de antibioticos para proporcionar una solucion total al tratamiento de infecciones.
EP1848413B1 (en) * 2005-02-14 2014-04-09 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
CA2626273C (en) * 2005-10-29 2013-05-14 Intervet International Bv Cefquinome compositions and methods of their use
US20080103121A1 (en) * 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
CA2713989A1 (en) * 2008-03-04 2009-09-11 Elan Pharma International Limited Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8849441B2 (en) 2008-10-31 2014-09-30 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8545806B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8858912B2 (en) 2008-10-31 2014-10-14 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
KR102329764B1 (ko) * 2013-03-15 2021-11-23 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
PT3319596T (pt) * 2015-07-09 2024-01-17 Uniwell Laboratories Llc Composições farmacêuticas
KR102740598B1 (ko) 2015-09-07 2024-12-09 모찌다 세이야쿠 가부시끼가이샤 알긴산 동결 건조 제제
TW201920174A (zh) 2017-09-27 2019-06-01 瑞士商羅氏大藥廠股份有限公司 二氮雜雙環辛烷衍生物之醫藥形式及其製法
EP3687504B1 (en) 2017-09-27 2024-11-27 Meiji Seika Pharma Co., Ltd. Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
KR20200091395A (ko) 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법
GB2575261B (en) 2018-07-02 2022-03-09 Norbrook Lab Ltd Intermediates in the synthesis of C3-substituted cephalosporins
CN109393004A (zh) * 2018-09-28 2019-03-01 上海锦立保鲜科技有限公司 一种利用冻品自由水升华实现真空解冻的方法
MX2024006239A (es) * 2021-11-26 2024-06-11 Astellas Pharma Inc Composicion farmaceutica solida que contiene el compuesto indocianina.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002748A (en) * 1976-01-19 1977-01-11 Eli Lilly And Company Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS6045514A (ja) * 1983-08-22 1985-03-12 Shionogi & Co Ltd 安定な抗菌性凍結乾燥製剤
SE8500273D0 (sv) * 1985-01-22 1985-01-22 Leo Ab Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder
US5138066A (en) * 1987-08-14 1992-08-11 Hoffmann-La Roche, Inc. Intermediates for cephalosporins with sulfur-containing oxyimino side chain
EP0327364A1 (en) 1988-02-05 1989-08-09 Eli Lilly And Company Crystalline beta-lactam solvate
CA2024587A1 (en) * 1989-09-05 1991-03-06 Bernard Ecanow Drug delivery compositions based on biological cells or components thereof and methods
US6001997A (en) * 1990-07-24 1999-12-14 Bateson; John Hargreaves Cephalosporins and homologues, preparations and pharmaceutical compositions
MY106399A (en) * 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
US6020329A (en) * 1990-07-24 2000-02-01 Pzifer Inc. Cephaloporins and homologues, preparations and pharmaceutical compositions
US5401842A (en) * 1992-09-08 1995-03-28 Bristol-Myers Squibb Company Injectable compositions of a cephalosporin dihydrate salt
EP0664117A1 (de) * 1994-01-25 1995-07-26 F. Hoffmann-La Roche Ag Liposomenlösungen
US5665760A (en) * 1995-09-18 1997-09-09 Sanofi Winthrop, Inc. Lyophilized thioxanthenone antitumor agents
KR100312622B1 (ko) * 1998-11-03 2002-02-28 김송배 생약을주성분으로한안정화된항암제조성물및그제조방법
JP2001199889A (ja) * 1999-11-11 2001-07-24 Takeda Chem Ind Ltd 縮合ピリダジン誘導体を含有してなる点鼻用剤
AU2023401A (en) 1999-12-01 2001-06-12 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
GB0002835D0 (en) * 2000-02-09 2000-03-29 Melvin William T Drug resistance in cancer
GB0019124D0 (en) 2000-08-03 2000-09-27 Pfizer Novel process
AU2002223943B2 (en) * 2000-12-04 2006-10-05 Pfizer Products Inc. Coupling process and intermediates useful for preparing cephalosphorins

Also Published As

Publication number Publication date
BRPI0214583B1 (pt) 2015-11-17
EP1448234B1 (en) 2008-09-03
HRP20040487A2 (en) 2004-10-31
EA008503B1 (ru) 2007-06-29
TW200300351A (en) 2003-06-01
KR100621291B1 (ko) 2006-09-13
PT1448234E (pt) 2008-10-02
IS7214A (is) 2004-04-07
AU2002348986A1 (en) 2003-06-10
TNSN04097A1 (fr) 2006-06-01
TWI248363B (en) 2006-02-01
NO20042271L (no) 2004-07-22
DK1448234T3 (da) 2008-11-03
CN1604793A (zh) 2005-04-06
IL161851A0 (en) 2005-11-20
US7378408B2 (en) 2008-05-27
US20030186957A1 (en) 2003-10-02
DE60228749D1 (de) 2008-10-16
PL212683B1 (pl) 2012-11-30
CY1108437T1 (el) 2014-04-09
AU2002348986B2 (en) 2008-04-03
JP4689959B2 (ja) 2011-06-01
BR0214583A (pt) 2004-11-03
PL370083A1 (en) 2005-05-16
ES2307800T3 (es) 2008-12-01
CA2468708C (en) 2008-08-19
AR037595A1 (es) 2004-11-17
ATE406916T1 (de) 2008-09-15
CA2468708A1 (en) 2003-06-05
EA200400489A1 (ru) 2004-10-28
HK1071292A1 (zh) 2005-07-15
NO334818B1 (no) 2014-06-02
CN100502873C (zh) 2009-06-24
WO2003045435A1 (en) 2003-06-05
MXPA04003724A (es) 2005-04-08
JP2005511642A (ja) 2005-04-28
IL161851A (en) 2011-11-30
KR20040058345A (ko) 2004-07-03
NZ532208A (en) 2007-01-26
EP1448234A1 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
TNSN04097A1 (fr) Formulations comprenant une cephalosporine et leur utilisation dans le traitement d'infections bacteriennes chez les chats et les chiens.
MA26770A1 (fr) Diarylamines substituees par 1-heterocycle.
MA28003A1 (fr) [1,8] naphtyridine-2-ones et composes apparentes pour le traitement de la schizophrenie
MA25009A1 (fr) Procede de preparation de composes derives de la piperidine pour la preparation de compositions antibacteriennes
GEP20053429B (en) 3-Aminoquinazolin-2,4-Dione, Pharmaceutical Composition Containing Them and Use Thereof as Antibacterial Agents
DE602004026053D1 (enExample)
ZA200507070B (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
EP1594444A3 (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
MA26703A1 (fr) Macrolides antibiotiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN05202A1 (fr) Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
MA27021A1 (fr) Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant
WO2005054234A8 (en) Substituted piperidino phenyloxazolidinones having antimicriobial activity with improved in vivo efficacy
ATE417915T1 (de) Reinigungsaktive und desinfizierende zusammensetzung
TNSN00103A1 (fr) Formes cristallines nouvelles d'un antibiotique macrolide, procede pour leur preparation et compositions pharmaceutiques les contenant
AU4568400A (en) Sphingomyelinase inhibitor
EP1585478A4 (en) USE OF SYNERGISTIC LYTIC ENZYMES FROM BACTERIOPHAGES FOR THE PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS
FR2821721B1 (fr) Composition pour alimentation animale, utilisation de cette composition, et produit pour alimentation animale comprenant cette composition
WO2001077365A3 (en) Antimicrobial methods and materials
EP1439840A4 (en) MONOBACTAM ANTIBACTERIAL COMPOUNDS AND METHOD OF USE
BR9803443A (pt) Composição antimicrobiana.
TNSN99084A1 (fr) Derives de 2 " - desoxy - hygromycine a nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
ATE315038T1 (de) Antibakterielle mittel